100%
 07:35
 0

 14 Nov
 235u

 222
 9.0

 118
 114

 114
 110

 116
 114

 116
 114

 116
 114

 110
 6

 122
 9.0

 INSULIN ON BOARD
 3.4 u

 110
 6

 110
 6

 110
 6

 110
 6

 110
 6

 110
 6

 110
 6

 110
 6

 110
 6

 111
 0.80 u

 0.80 u
 0.80 u

CLINICAL STUDY RESULTS



Average additional time in range per day for study participants who used Control-IQ technology.¹



Percent of study participants who used Control-IQ technology and **said it was** easy to use.² * As measured by CGM. † If glucose values are predicted to be above 10.0 mmol/L, Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 6.1 mmol/L and delivers 60% of that value. An Automatic Correction Bolus will not occur within 60 minutes of a bolus that has been delivered or cancelled. ‡ If your glucose alerts and readings from the Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

References: 1. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. *NEng JMed*. 2019;381(18):1701-1717. 2. Brown, S. Clinical Acceptance of the Artificial Pancreas: Glycemia Outcomes from a 6-month Multicenter RCT. 2019 ADA 79th Scientific Sessions, San Francisco, CA. 3. 38% smaller than MiniMed 630G and 670G and at least 28% smaller than MiniMed 530G, Animas Vibe, and Omnipod System. Data on file, Tandem Diabetes Care.

Important Safety Information: The t:slim X2[™] insulin pump with Control-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Control-IQ technology, and a compatible continuous glucose monitor (CGM, sold separately). The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When used with a compatible CGM, the System can be used to automatically increase, decrease, and suspend delivery of basal insulin based on CGM sensor readings and predicted glucose values. The System can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. The pump and the System are indicated for use in individuals six years of age and greater. The pump and the System are indicated for use in individuals user. The pump and the System are indicated for use with NovoRapid or Humalog U-100 insulin. The System is intended for the management of Type 1 diabetes.

WARNING: The t:slim X2 pump with Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 25 kilograms.

The System is not indicated for use in pregnant women, people on dialysis, or critically ill users. Do not use the System if using hydroxyurea. Users of the pump and the System must: be willing and able to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognise all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump and the CGM transmitter and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/ safetyinfo for additional important safety information.

© 2021 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Control-IQ, and t:slim X2 are either trademarks or registered trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries.Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries. All other third-party marks are the property of their respective owners.

Distributed in New Zealand by New Zealand Medical & Scientific Ltd, 2A Fisher Crescent, Mt Wellington, Auckland 1060, P 09 259 4062. NZDI_TAN_093



t:slim X2 Insulin Pump with Control-IQ TECHNOLOGY

See How Easy Control Can Be



Control-IQ technology does not prevent all highs and lows. Users must still bolus for meals and actively manage their diabetes. Please visit tandemdiabetes.com/tslimX2-use for more info.



P: 0800 500 226 |E: diabetes@nzms.co.nz 24/7 Customer Care: 0508 634 103 nzmsdiabetes.co.nz

Introducing Control-IQ Technology

Trying to keep your blood sugar in range can be stressful and time consuming. Our new Control-IQ[™] advanced hybrid closed-loop technology makes it easier by predicting and helping prevent both highs and lows.



How Does it Work?

Control-IQ technology is designed to help increase time in range (3.9-10.0 mmol/L)* using Dexcom G6 CGM values to predict glucose levels 30 minutes ahead and adjust insulin delivery accordingly, including delivery of automatic correction boluses[†] up to once per hour. There are also additional settings for Sleep and Exercise.



* As measured by CGM. † Users must still bolus for meals and actively manage their diabetes. For more information on automatic correction boluses, see back cover. ‡ If your glucose alerts and readings from the Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.